« Return to News | Drug Sponsors | R&D Trends

Russian firms join in $113 million R&D project

Tuesday, August 9, 2011 11:49 AM

Several Russian companies have linked up to establish a joint venture designed to develop innovative treatments in the country, according to PharmaTimes.

The SynBio project has been initiated by the Human Stem Cells Institute (HSCI), Russia's leading biotechnology company, which will have a 28.1% stake in the venture. It has attracted investment from the government-owned investment company Rusnano, which will have a 41.4% holding and other Russian firms involved include Cryonix and Pharmsynthez.

The lead R&D partner for the project is the UK's Lipoxen, which is in the process of merging with Germany's SymbioTec. SynBio will focus on developing treatments based on three technological platforms.  It will look at drugs engineered from cell-based technologies for the treatment of chronic diffuse liver disease and treatments based on the human nuclear protein histone H1 for cancer and other diseases.

SynBio will also focus on "sustained-release drugs using polysialic acid", such as 'biobetters' for the treatment of diabetes, Alzheimer's, chronic kidney disease and a number of other conditions. The total budget for the project over the next four years amounts to roughly $113 million.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.